Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Maker FTC Clarifies Rules Regarding Dispatch of Doctors Abroad
July 30, 2001
- Zyvox Effectiveness against VRE Reported: Pharmacia Forum
July 30, 2001
- Sanko Junyaku Patents Gene Amplification Method in the US
July 30, 2001
- Edible Plants Effective for Peripheral Neuropathy: Takara Shuzo
July 30, 2001
- REGULATORY NEWS IN BRIEF -2-
July 30, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
July 30, 2001
- REGULATORY NEWS IN BRIEF -2-
July 30, 2001
- Most Top Management of Wholesalers Regard Current Sales Prices as Abnormal: Survey
July 30, 2001
- Ticlopidine Continues to Cause Serious ADRs: Korosho
July 30, 2001
- FALCO biosystems to Take Over Lab Test Business from Subsidiary
July 30, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
July 30, 2001
- Checklist Issued for Clinical Trials of Medical Devices
July 30, 2001
- JMA, JDA, JPA Join Hands to Oppose Government's Reform Proposals
July 30, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
July 23, 2001
- BUSINESS NEWS IN BRIEF -2-
July 23, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 23, 2001
- BUSINESS NEWS IN BRIEF -1-
July 23, 2001
- Compact, Inexpensive Accelerators Necessary: Monkasho Survey
July 23, 2001
- Only 16% of Citizens Use Life-style Improving Drugs: Survey
July 23, 2001
- Kyowa Hakko to Start Marketing Cholesterol-lowering Super Soy in the US, Europe
July 23, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…